Multiple myeloma-derived Jagged ligands increases autocrine and paracrine interleukin-6 expression in bone marrow niche.
Colombo M et al. Oncotarget. 2016 Jul 24. doi: 10.18632/oncotarget.10820. [Epub ahead of print].

HLA polymorphism and risk of multiple myeloma.
Beksac M et al. Leukemia. 2016 Jul 27. doi: 10.1038/leu.2016.199. [Epub ahead of print].

Cereblon and its downstream substrates as molecular targets of immunomodulatory drugs.
Ito T et al. Int J Hematol. 2016 Jul 26. [Epub ahead of print].

Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes.
Kortüm KM et al. Blood. 2016 Jul 25. pii: blood-2016-02-698092. [Epub ahead of print].

BCL-B (BCL2L10) is overexpressed in patients suffering from multiple myeloma (MM) and drives an MM-like disease in transgenic mice.
Hamouda MA et al. J Exp Med. 2016 Jul 25. pii: jem.20150983. [Epub ahead of print].

Genomic Studies of Multiple Myeloma Reveal an Association between X Chromosome Alterations and Genomic Profile Complexity.
Sticca T et al. Genes Chromosomes Cancer. 2016 Jul 25. doi: 10.1002/gcc.22397. [Epub ahead of print].

Carfilzomib significantly improves the progression free survival of high-risk patients in multiple myeloma.
Avet-Loiseau H et al. Blood. 2016 Jul 20. pii: blood-2016-03-707596. [Epub ahead of print].

Genetic Susceptibility to Bortezomib-Induced Peripheral Neuroropathy: Replication of the Reported Candidate Susceptibility Loci.
Campo C et al. Neurochem Res. 2016 Jul 16. [Epub ahead of print].

Genome-wide association study identifies multiple susceptibility loci for multiple myeloma.
Mitchell JS et al. Nat Commun. 2016 Jul 1;7:12050. doi: 10.1038/ncomms12050.

A common variant within the HNF1B gene is associated with overall survival of multiple myeloma patients: Results from the IMMEnSE consortium and meta-analysis.
Ríos-Tamayo R et al. Oncotarget. 2016 Jul 18. doi: 10.18632/oncotarget.10665. [Epub ahead of print].

Outcomes in patients with multiple myeloma with TP53 deletion after autologous hematopoietic stem cell transplant.
Gaballa S et al. Am J Hematol. 2016 Jul 15. doi: 10.1002/ajh.24487. [Epub ahead of print].

DNA repair of myeloma plasma cells correlates with clinical outcome; the effect of the non-homologous end-joining inhibitor SCR7.
Gkotzamanidou M et al. Blood. 2016 Jul 21. pii: blood-2016-01-691618. [Epub ahead of print].

Biclonal plasma cell myeloma with the simultaneous appearance of both secretory lambda and nonsecretory kappa monoclonal light chains.
Gu HJ et al. Clin Chem Lab Med. 2016 Jul 21. pii: /j/cclm.ahead-of-print/cclm-2016-0364/cclm-2016-0364.xml. doi: 10.1515/cclm-2016-0364. [Epub ahead of print].

Myeloma drug resistance induced by binding of myeloma B7-H1 (PD-L1) to PD-1.
Ishibashi M et al. Cancer Immunol Res. 2016 Jul 20. pii: canimm.0296.2015. [Epub ahead of print].

The novel pan-PIM kinase inhibitor, PIM447, displays dual anti-myeloma and bone protective effects, and potently synergizes with current standards of care.
Paíno T et al. Clin Cancer Res. 2016 Jul 20. pii: clincanres.0230.2016. [Epub ahead of print].

Novel phosphatidylinositol 3-kinase inhibitor BKM120 enhances the sensitivity of multiple myeloma to bortezomib and overcomes resistance.
Yu W et al. Leuk Lymphoma. 2016 Jul 20:1-10. [Epub ahead of print].

Proteasome inhibition correlates with intracellular bortezomib concentrations but not with antiproliferative effects after bolus treatment in myeloma cell lines.
Dettmer S et al. Naunyn Schmiedebergs Arch Pharmacol. 2016 Jul 15. [Epub ahead of print].

The antibiotic chloramphenicol may be an effective new agent for inhibiting the growth of multiple myeloma.
Tian F et al. Oncotarget. 2016 Jul 16. doi: 10.18632/oncotarget.10623. [Epub ahead of print].

Bruceantin inhibits multiple myeloma cancer stem cell proliferation.
Issa ME et al. Cancer Biol Ther. 2016 Jul 19:0. [Epub ahead of print].

Metabotropic glutamate receptor 3 is involved in B-cell-related tumor apoptosis.
Liu X et al. Int J Oncol. 2016 Jul 15. doi: 10.3892/ijo.2016.3623. [Epub ahead of print].

Paeoniflorin inhibits proliferation and promotes apoptosis of multiple myeloma cells via its effects on microRNA‑29b and matrix metalloproteinase‑2.
Wang S et al. Mol Med Rep. 2016 Jul 11. doi: 10.3892/mmr.2016.5498. [Epub ahead of print].

Combined therapeutic effects of bortezomib and anacardic acid on multiple myeloma cells via activation of the endoplasmic reticulum stress response.
Dong X et al. Mol Med Rep. 2016 Jul 19. doi: 10.3892/mmr.2016.5533. [Epub ahead of print].

Targeting KIR blockade in Multiple Myeloma: trouble in checkpoint paradise?
Felices M et al. Clin Cancer Res. 2016 Jul 18. pii: clincanres.1582.2016. [Epub ahead of print].

Increase of CIK cell efficacy by upregulating cell surface MICA and inhibition of NKG2D ligand shedding in multiple myeloma.
Nwangwu CA et al. Hematol Oncol. 2016 Jul 19. doi: 10.1002/hon.2326. [Epub ahead of print].

Inhibition of multiple myeloma cell proliferation by ginsenoside Rg3 via reduction in the secretion of IGF-1.
Li Y et al. Mol Med Rep. 2016 Jul 7. doi: 10.3892/mmr.2016.5475. [Epub ahead of print].

Combined treatment with a transforming growth factor beta inhibitor (1D11) and bortezomib improves bone architecture in a mouse model of myeloma-induced bone disease.
Nyman JS et al. Bone. 2016 Jul 14;91:81-91. doi: 10.1016/j.bone.2016.07.007. [Epub ahead of print].

Intracellular glutathione determines bortezomib cytotoxicity in multiple myeloma cells.
Starheim KK et al. Blood Cancer J. 2016 Jul 15;6(7):e446. doi: 10.1038/bcj.2016.56.

Osteoclasts promote immune suppressive microenvironment in multiple myeloma: therapeutic implication.
An G et al. Blood. 2016 Jul 14. pii: blood-2016-03-707547. [Epub ahead of print].

Cucurbitacin B exerts anti-cancer activities in human multiple myeloma cells in vitro and in vivo by modulatingmultiple cellular pathways.
Yang T et al. Oncotarget. 2016 Jul 13. doi: 10.18632/oncotarget.10584. [Epub ahead of print].

Epigenetic mechanisms of cell adhesion-mediated drug resistance in multiple myeloma.
Furukawa Y et al, Int J Hematol. 2016 Jul 13. [Epub ahead of print].

Identification of candidate genes for myeloma-induced osteocyte death based on microarray data.
Tian H et al. J Orthop Surg Res. 2016 Jul 12;11(1):81. doi: 10.1186/s13018-016-0411-0.

Sequential CCR5-Tropic HIV-1 Reactivation from Distinct Cellular Reservoirs following Perturbation of Elite Control.
Watters SA et al. PLoS One. 2016 Jul 12;11(7):e0158854. doi: 10.1371/journal.pone.0158854. eCollection 2016.

Citrullination of histone H3 drives IL-6 production by bone marrow mesenchymal stem cells in MGUS and multiple myeloma.
McNee G et al. Leukemia. 2016 Jul 11. doi: 10.1038/leu.2016.187. [Epub ahead of print].

Raiders of the lost mark – endothelial cells and their role in transplantation for hematologic malignancies.
Blix ES et al. Leuk Lymphoma. 2016 Jul 10:1-11. [Epub ahead of print].

New mAb therapies in multiple myeloma: interference with blood transfusion compatibility testing.
De Vooght KM et al. Curr Opin Hematol. 2016 Jul 6. [Epub ahead of print].

Role of Myeloma-Derived MIF in Myeloma Cell Adhesion to Bone Marrow and Chemotherapy Response.
Zheng Y et al. J Natl Cancer Inst. 2016 Jul 5;108(11). pii: djw131. doi: 10.1093/jnci/djw131. Print 2016 Nov.

Backbone resonance assignments for the SET domain of the human methyltransferase NSD2.
Bobby R et al. Biomol NMR Assign. 2016 Jul 1. [Epub ahead of print].

Gene-expression Profiling in Patients with Plasma Cell Myeloma Treated with Novel Agents.
Medinger M et al. Cancer Genomics Proteomics. 2016 07-08;13(4):275-279.

Syndecan-1 (CD138) suppresses apoptosis in multiple myeloma by activating IGF1 receptor: prevention by synstatinIGF1R inhibits tumor growth.
Beauvais DM et al. Cancer Res. 2016 Jun 30. pii: canres.0232.2016. [Epub ahead of print].

Targeted immunotherapy using anti-CD138-interferon α fusion proteins and bortezomib results in synergistic protection against multiple myeloma.
Vasuthasawat A et al. MAbs. 2016 Jun 30:0. [Epub ahead of print].

Clofibrate Demonstrates Efficacy in In Vitro Treatment of Lymphoma and Multiple Myeloma.
Schmeel LC et al. Anticancer Res. 2016 Jul;36(7):3395-400.

Clinical Pharmacokinetics and Pharmacodynamics of Lenalidomide.
Chen N et al. Clin Pharmacokinet. 2016 Jun 28. [Epub ahead of print].

3-Formylchromone inhibits proliferation and induces apoptosis of multiple myeloma cells by abrogating STAT3 signaling through the induction of PIAS3.
Ko JH et al. Immunopharmacol Immunotoxicol. 2016 Jul 7:1-10. [Epub ahead of print].